letrozole / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 114 Diseases   361 Trials   361 Trials   7200 News 


«12...8788899091929394959697...100101»
  • ||||||||||  letrozole / Generic mfg.
    Trial completion, Enrollment change, Trial initiation date, Trial primary completion date:  Aromatase Inhibitor Effects on Ovarian Function During the Follicular and Early Luteal Phase in Women (clinicaltrials.gov) -  Jan 26, 2016   
    P4,  N=41, Completed, 
    Trial primary completion date: May 2016 --> May 2017 Recruiting --> Completed | N=80 --> 41 | Initiation date: Jan 2009 --> Jan 2010 | Trial primary completion date: Feb 2011 --> Feb 2012
  • ||||||||||  letrozole / Generic mfg., clomifene citrate / Generic mfg.
    New trial:  A Comparison of Letrozole and Clomifene Citrate (clinicaltrials.gov) -  Jan 6, 2016   
    P=N/A,  N=40, Recruiting, 
  • ||||||||||  Enrollment open, Metastases:  POLLY: ER Reactivation Therapy for Breast Cancer (clinicaltrials.gov) -  Dec 9, 2015   
    P2,  N=59, Recruiting, 
    Trial primary completion date: Mar 2016 --> Mar 2017 Active, not recruiting --> Recruiting
  • ||||||||||  letrozole / Generic mfg., clomifene citrate / Generic mfg.
    Trial completion, Enrollment change, Trial primary completion date:  COOL-COS: COmbining Oral Letrozole and Clomiphene for Ovarian Stimulation (clinicaltrials.gov) -  Dec 4, 2015   
    P4,  N=28, Completed, 
    Active, not recruiting --> Recruiting Enrolling by invitation --> Completed | N=40 --> 28 | Trial primary completion date: Oct 2015 --> Mar 2015
  • ||||||||||  Piqray (alpelisib) / Novartis, Kisqali (ribociclib) / Novartis
    Phase classification, Enrollment change, Metastases:  CLEE011X2107: Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer (clinicaltrials.gov) -  Nov 16, 2015   
    P1,  N=200, Recruiting, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2017 --> Aug 2019 Phase classification: P1/2 --> P1 | N=300 --> 200
  • ||||||||||  letrozole / Generic mfg.
    Trial completion, Enrollment change, Trial primary completion date:  Study of Breast Cancer Prevention by Letrozole in High Risk Women (clinicaltrials.gov) -  Nov 10, 2015   
    P2,  N=55, Completed, 
    Trial primary completion date: Dec 2016 --> Dec 2017 Active, not recruiting --> Completed | N=108 --> 55 | Trial primary completion date: Jul 2015 --> Mar 2015
  • ||||||||||  letrozole / Generic mfg., sorafenib / Generic mfg.
    Trial primary completion date, Metastases:  Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer (clinicaltrials.gov) -  Nov 9, 2015   
    P1/2,  N=54, Active, not recruiting, 
    Active, not recruiting --> Completed | N=108 --> 55 | Trial primary completion date: Jul 2015 --> Mar 2015 Trial primary completion date: Dec 2015 --> May 2016
  • ||||||||||  letrozole / Generic mfg.
    Enrollment closed, Trial primary completion date:  Aromatase Inhibitor Host Factors Study (clinicaltrials.gov) -  Oct 20, 2015   
    P=N/A,  N=140, Active, not recruiting, 
    Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2015 --> Jun 2015
  • ||||||||||  letrozole / Generic mfg.
    Trial completion, Trial primary completion date, Metastases:  Intermittent Letrozole Therapy in Postmenopausal Women With Metastatic Breast Cancer (clinicaltrials.gov) -  Oct 7, 2015   
    P2,  N=3, Completed, 
    Trial primary completion date: Nov 2016 --> Dec 2015 Active, not recruiting --> Completed | Trial primary completion date: Mar 2014 --> May 2010
  • ||||||||||  Herceptin (trastuzumab) / Roche, Kisqali (ribociclib) / Novartis, Perjeta (pertuzumab) / Roche
    Enrollment open, Trial initiation date, Trial primary completion date:  Detect V / CHEVENDO (Chemo vs. Endo) (clinicaltrials.gov) -  Sep 2, 2015   
    P3,  N=270, Recruiting, 
    Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Apr 2015 --> Sep 2015 | Trial primary completion date: Mar 2021 --> Sep 2021